Seeking Alpha EN

Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M

Mar 10, 2026 &03101010202631; 10:10 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -35/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Esperion Therapeutics reported Q3 GAAP EPS of $0.22, missing analyst expectations by $0.05, though revenue of $168.45M exceeded estimates by $2.33M. The mixed earnings result shows revenue strength offset by profitability concerns, likely pressuring the stock in near-term trading.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

ESPR

ESPRStock

Expected to decline

EPS miss of $0.05 indicates profitability underperformance despite revenue beat, typically triggering negative market reaction

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Short-term bearish bias on ESPR due to earnings miss despite revenue strength. Monitor guidance and margin commentary in earnings call; consider waiting for stabilization before entry. Risk/reward favors shorts on any near-term rallies.

KEY SIGNALS

EPS miss signals margin compression or higher operating expensesRevenue beat demonstrates demand strength for productsDivergence between revenue and earnings growth raises efficiency concernsPotential guidance revision risk if profitability trend continues

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 11, 2026 at 03:25 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M

RELATED INTELLIGENCE